Troels H. Borch, MD, PhD

MD
National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte,Herlev, Denmark, Denmark

Presentation(s):

• 61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.

  Thursday, March 21, 2024
  2:07pm – 2:17pm ET